Thacapzol (Thiamazole)
Antithyroid medication for the treatment of hyperthyroidism
Quick Facts about Thacapzol
Key Takeaways about Thacapzol
- Treats overactive thyroid: Thacapzol (thiamazole) is the first-line medication for hyperthyroidism, including Graves' disease and toxic goiter
- Watch for infection signs: Seek immediate medical attention if you develop fever, sore throat, or mouth ulcers, as these may indicate a serious drop in white blood cells (agranulocytosis)
- Pregnancy risk: Thiamazole can cause birth defects — reliable contraception is essential during treatment, and your doctor should be informed immediately if you become pregnant
- Takes weeks to work: Existing thyroid hormone stores must be depleted first, so clinical improvement typically begins after 1–3 weeks
- Regular monitoring required: Blood tests for thyroid function and blood cell counts should be performed regularly throughout treatment
What Is Thacapzol and What Is It Used For?
Thacapzol contains thiamazole, an antithyroid medication that accumulates in the thyroid gland and potently inhibits the production of thyroid hormones T3 (triiodothyronine) and T4 (thyroxine). It is the standard first-line treatment for hyperthyroidism, used in conditions such as Graves' disease and toxic multinodular goiter.
The thyroid gland, located in the front of the neck, produces hormones that regulate the body's metabolism, heart rate, body temperature, and energy levels. In hyperthyroidism, the thyroid becomes overactive and produces excessive amounts of these hormones, leading to a wide range of symptoms including rapid or irregular heartbeat, unintentional weight loss, anxiety, tremors, sweating, and heat intolerance.
Thiamazole belongs to the thionamide class of antithyroid drugs. It works by inhibiting thyroid peroxidase (TPO), an enzyme that plays a central role in the synthesis of thyroid hormones. By blocking this enzyme, thiamazole prevents the iodination and coupling steps required to produce T3 and T4. This mechanism of action is shared with carbimazole (a prodrug that is converted to thiamazole in the body) and propylthiouracil (PTU), though PTU additionally inhibits the peripheral conversion of T4 to T3.
Thacapzol is prescribed for several clinical scenarios. In newly diagnosed Graves' disease, it is often the initial treatment of choice, with treatment typically lasting 12 to 18 months to achieve long-term remission. It is also used as preparatory treatment before thyroid surgery (thyroidectomy) or radioactive iodine therapy, where the goal is to render the patient euthyroid (normal thyroid function) before the procedure. In thyroid storm, a life-threatening exacerbation of hyperthyroidism, high-dose thiamazole is administered as part of the emergency treatment protocol.
Clinical evidence supports thiamazole as the preferred first-line antithyroid drug in most situations. The American Thyroid Association (ATA) and the European Thyroid Association (ETA) both recommend thiamazole over propylthiouracil for the initial treatment of Graves' disease, except during the first trimester of pregnancy, where PTU is preferred due to the teratogenic risks associated with thiamazole.
Carbimazole is a prodrug that the body converts into thiamazole. While both produce the same active compound, the dosing differs slightly. Approximately 10 mg of carbimazole yields about 6 mg of thiamazole. In countries where carbimazole is more commonly used (e.g., the United Kingdom), the same clinical principles apply, but the prescribed doses will be adjusted accordingly.
What Should You Know Before Taking Thacapzol?
Before starting Thacapzol, your doctor must evaluate your liver function, pregnancy status, and medication history. Important contraindications include allergy to thiamazole or carbimazole, and a history of acute pancreatitis caused by thiamazole or carbimazole.
Contraindications
You must not take Thacapzol if you are allergic to thiamazole or any of the other ingredients in the tablets (lactose monohydrate, microcrystalline cellulose, magnesium stearate, anhydrous colloidal silicon dioxide). You should also not take this medication if you have previously had acute pancreatitis (inflammation of the pancreas) caused by thiamazole or carbimazole treatment.
Patients with a history of severe hypersensitivity reactions to either thiamazole or carbimazole should not receive Thacapzol, as cross-reactivity between the two drugs is common. In such cases, alternative treatment approaches such as surgery or radioactive iodine therapy should be considered.
Warnings and Precautions
Speak with your doctor or nurse before taking Thacapzol if you have impaired liver function. Thiamazole can cause hepatotoxicity, and patients with pre-existing liver disease may be at higher risk. Liver function tests should be performed before starting treatment and monitored periodically throughout therapy.
If you develop fever, sore throat, mouth ulcers, or any other serious signs of infection during treatment with Thacapzol, contact your doctor immediately for an urgent blood test. Agranulocytosis (a severe reduction in white blood cells) is a rare but potentially life-threatening side effect that typically occurs within the first 3 months of treatment. If agranulocytosis is confirmed, thiamazole must be stopped immediately and should never be restarted.
If you experience sudden, severe abdominal pain while taking Thacapzol, tell your doctor immediately. This could indicate acute pancreatitis, a serious condition requiring immediate discontinuation of the medication. Pancreatitis has been reported in patients taking thiamazole, and it can recur if the drug is restarted.
Thacapzol is not recommended for children under 2 years of age due to limited safety data in this age group. For older children and adolescents, the medication can be used under careful medical supervision with appropriate dose adjustments based on body weight.
Thacapzol tablets contain lactose. If you have been diagnosed with a lactose intolerance, consult your doctor before taking this medication, as even the small amount of lactose present in the tablets may cause symptoms in individuals with severe galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Pregnancy and Breastfeeding
Thiamazole crosses the placenta and has been associated with congenital malformations, including aplasia cutis (skin defects on the scalp), choanal atresia (blockage of the nasal passages), and other birth defects collectively known as methimazole/carbimazole embryopathy. These risks are highest during the first trimester, particularly between weeks 6 and 10 of gestation.
If you are of childbearing potential, you should use reliable contraception from the start of treatment and throughout the duration of therapy. If you become pregnant or suspect you may be pregnant, contact your doctor immediately. In some cases, the benefits of continuing thiamazole during pregnancy may outweigh the risks, particularly when severe hyperthyroidism poses a threat to both the mother and the fetus. However, the American Thyroid Association recommends switching to propylthiouracil (PTU) during the first trimester, as PTU has a lower teratogenic risk during this period.
Thiamazole is excreted in breast milk. Breastfeeding should be discontinued during treatment with Thacapzol. However, some international guidelines (e.g., ATA 2017) suggest that low-dose thiamazole (up to 20 mg/day) may be compatible with breastfeeding under close monitoring. Discuss the risks and benefits with your healthcare provider.
Driving and Operating Machinery
No adverse effects on the ability to drive or operate machinery have been observed with thiamazole. However, untreated or inadequately controlled hyperthyroidism itself can cause nervousness, tremor, and difficulty concentrating, which may impair your ability to drive safely. Ensure your thyroid condition is adequately managed before undertaking activities that require alertness.
How Does Thacapzol Interact with Other Drugs?
Thacapzol can interact with several commonly used medications. The most clinically significant interactions involve cardiac glycosides (digoxin), anticoagulants (warfarin), and bronchodilators (theophylline). Your doctor may need to adjust the doses of these medications during and after antithyroid treatment.
Drug interactions with thiamazole are primarily related to changes in thyroid function rather than direct pharmacokinetic interactions. As hyperthyroidism is treated and thyroid hormone levels return to normal, the metabolism of many drugs changes significantly. This means that medications whose dosing was established during the hyperthyroid state may need to be re-evaluated as thyroid function normalizes.
Your doctor should also be aware if you are scheduled for any imaging procedures requiring iodinated contrast media. Iodine-containing contrast agents can interfere with thyroid function and antithyroid treatment. Your doctor may ask you to pause Thacapzol temporarily before and after the procedure.
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Digoxin (cardiac glycoside) | Digoxin levels may increase as hyperthyroidism is corrected, since the clearance of digoxin is reduced in the euthyroid state | Monitor digoxin levels closely; dose reduction may be needed |
| Warfarin (anticoagulant) | Warfarin effect may increase as thyroid function normalizes, because hyperthyroidism accelerates the catabolism of vitamin K-dependent clotting factors | Monitor INR frequently; warfarin dose adjustment usually needed |
| Theophylline (bronchodilator) | Theophylline clearance decreases as the patient becomes euthyroid, potentially leading to toxicity | Monitor theophylline levels; dose reduction may be required |
| Iodinated contrast media | Iodine load can worsen hyperthyroidism or interfere with antithyroid treatment efficacy | Pause Thacapzol as directed by your doctor before the procedure |
| Beta-blockers (e.g., propranolol) | Often co-prescribed to control symptoms; beta-blocker dose may need adjustment as thyroid function normalizes | Gradual dose reduction of beta-blocker as symptoms improve |
Always inform your doctor, pharmacist, or nurse about all medications you are currently taking, have recently taken, or might take. This includes over-the-counter medications, herbal supplements, and vitamins, as some may contain iodine or other substances that can affect thyroid function.
What Is the Correct Dosage of Thacapzol?
The dosage of Thacapzol is individualized based on the severity of hyperthyroidism. For adults, the typical starting dose is 10–40 mg daily, usually divided into two doses. Children receive 0.5 mg/kg/day. Tablets should be swallowed whole with liquid, without chewing.
Always take this medication exactly as your doctor has prescribed. Do not change your dose or stop taking Thacapzol without consulting your doctor first, as abruptly stopping treatment can lead to a rebound in thyroid hormone levels. Your doctor will regularly check your thyroid function with blood tests and adjust the dose accordingly.
Adults
Adult Dosing
For long-term treatment of hyperthyroidism, the recommended starting dose is 1–4 tablets (5–20 mg) twice daily. The starting dose should be tailored to the severity of the disease. In mild cases, a lower starting dose may be sufficient, while severe or complicated hyperthyroidism may require higher initial doses of up to 40 mg per day.
Once thyroid function has normalized (usually after 4–8 weeks), the dose is gradually reduced to the lowest effective maintenance dose, typically 5–10 mg per day. Treatment with thiamazole for Graves' disease usually continues for 12–18 months to maximize the chance of long-term remission.
There are two main strategies for long-term treatment: the titration regimen (dose is adjusted down as thyroid function improves) and the block-and-replace regimen (a higher dose of thiamazole is maintained together with levothyroxine to replace blocked thyroid function). Your doctor will decide which approach is best for your situation.
Children and Adolescents (2–17 years)
Pediatric Dosing
The usual starting dose for children is 0.5 mg/kg body weight per day, divided into 2 or 3 equal doses. The total daily dose should not exceed 40 mg. As with adults, the dose is adjusted based on thyroid function tests and reduced to the lowest effective maintenance dose once euthyroidism is achieved.
Thacapzol is not recommended for children under 2 years of age due to limited data on safety and efficacy in this age group.
Elderly Patients
Elderly Dosing
No specific dose adjustments are recommended for elderly patients. However, older adults may be more susceptible to side effects and may have co-existing conditions (such as heart disease) that require close monitoring. Your doctor may start with a lower dose and adjust gradually based on your response to treatment and any side effects that occur.
| Patient Group | Starting Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Adults | 5–20 mg twice daily | 5–10 mg/day | Adjust to disease severity; max 40 mg/day |
| Children (2–17 years) | 0.5 mg/kg/day in 2–3 doses | Individualized | Max 40 mg/day; not for under 2 years |
| Elderly | Start low, titrate up | Individualized | Monitor for cardiac and hepatic effects |
| Pre-surgical | Up to 40 mg/day | Until euthyroid | Goal: normalize thyroid function before surgery |
Missed Dose
If you forget to take a dose of Thacapzol, take it as soon as you remember, unless it is close to the time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Consistent dosing is important for maintaining stable thyroid hormone levels, so try to take your medication at the same times each day.
Overdose
If you have taken more Thacapzol than prescribed, or if a child has accidentally swallowed the medication, contact your doctor, hospital, or poison control center immediately. Symptoms of overdose may include nausea, vomiting, headache, and signs of hypothyroidism (such as fatigue, weight gain, cold intolerance, and constipation) if the overdose is sustained. Agranulocytosis and other bone marrow effects may also occur with large acute doses. Treatment is supportive, and thyroid function should be monitored closely.
What Are the Side Effects of Thacapzol?
Like all medications, Thacapzol can cause side effects, although not everyone will experience them. The most common side effects are skin rash, hives, and joint inflammation. The most serious potential side effect is agranulocytosis, a severe drop in white blood cells that can lead to life-threatening infections.
Side effects of thiamazole are generally dose-dependent, meaning they occur more frequently at higher doses. Most mild side effects improve when the dose is reduced. If you experience any concerning symptoms while taking Thacapzol, contact your doctor. Some side effects require urgent medical attention, particularly those suggesting bone marrow suppression or liver problems.
Common
Affects more than 1 in 100 patients
- Skin rash and urticaria (hives)
- Joint inflammation (arthralgia)
- Bone marrow suppression — reduced production of various blood cell types
Uncommon
Affects fewer than 1 in 100 patients
- Liver impairment — elevated liver enzymes, cholestatic hepatitis
Rare
Affects fewer than 1 in 1,000 patients
- Loss of taste (ageusia)
- Skin and mucous membrane inflammation
- Vasculitis (inflammation of blood vessels)
Frequency Not Known
Reported but frequency cannot be determined
- Insulin autoimmune syndrome — episodes of low blood sugar (hypoglycemia)
- Acute pancreatitis — inflammation of the pancreas with severe abdominal pain
- Cholestatic jaundice — yellowing of the skin and eyes due to impaired bile flow
If you develop an infection with symptoms such as fever with severely worsened general condition, or fever with localized infection symptoms such as sore throat, difficulty swallowing, mouth ulcers, or urinary symptoms, seek medical attention immediately. A blood test is essential to rule out agranulocytosis (a dangerous lack of white blood cells). Always inform the healthcare provider that you are taking thiamazole. This side effect most often occurs in the first 3 months of treatment and is more common at higher doses (above 30 mg/day).
If you notice any side effects not listed here, or if any of the listed effects become severe, please report them to your healthcare provider. Reporting suspected side effects helps regulatory authorities continuously monitor the benefit-risk balance of medications.
How Should You Store Thacapzol?
Store Thacapzol in its original packaging to protect it from light. Keep it at room temperature, out of the reach and sight of children, and do not use it after the expiry date.
Thacapzol tablets are light-sensitive and should always be kept in the original HDPE plastic container with the child-resistant cap securely closed. Store at room temperature, avoiding exposure to excessive heat, moisture, and direct sunlight. The expiry date (EXP) is printed on the label and refers to the last day of the indicated month.
Do not dispose of medications in household waste or via the drainage system. Return unused or expired medication to your pharmacy for proper disposal. These measures help protect the environment from unnecessary pharmaceutical contamination.
What Does Thacapzol Contain?
Each Thacapzol tablet contains 5 mg of the active substance thiamazole. The tablets are white, round, flat, scored, and engraved with “TH” within arches. They come in containers of 100 tablets.
Active Ingredient
Thiamazole 5 mg (also known internationally as methimazole) is the active substance responsible for the antithyroid effect. Thiamazole is a heterocyclic sulfur-containing compound that belongs to the imidazole family. It has a molecular weight of 114.17 g/mol and is well absorbed from the gastrointestinal tract after oral administration, with an oral bioavailability of approximately 93%.
Inactive Ingredients (Excipients)
- Lactose monohydrate — a sugar used as a filler and binder in the tablet
- Microcrystalline cellulose — a commonly used pharmaceutical excipient that aids tablet compression
- Magnesium stearate — a lubricant that prevents the tablet from sticking to manufacturing equipment
- Anhydrous colloidal silicon dioxide — a flow agent that ensures consistent drug distribution within each tablet
Appearance and Packaging
Thacapzol 5 mg tablets are white, round, flat tablets with a score line (allowing them to be split into halves) and engraved with "TH" within arches on one side. Each tablet has a diameter of 6 mm. They are packaged in white HDPE plastic containers with child-resistant lids, each containing 100 tablets.
The marketing authorization holder is Viatris AB. The tablets are manufactured by SIDEFARMA – Sociedade Industrial de Expansão Farmacêutica, S.A. in Portugal, or Fine Foods and Pharmaceuticals N.T.M. S.P.A. in Italy.
Frequently Asked Questions about Thacapzol
Thacapzol (thiamazole) is used to treat hyperthyroidism, a condition where the thyroid gland produces too much thyroid hormone. It works by inhibiting the enzyme thyroid peroxidase, which is essential for producing thyroid hormones T3 and T4. It is commonly prescribed for Graves' disease, toxic multinodular goiter, and as preparation for thyroid surgery or radioiodine therapy.
Thacapzol typically begins to reduce thyroid hormone levels within 1 to 3 weeks after starting treatment. However, full therapeutic effect may take 4 to 8 weeks as existing stores of thyroid hormone in the body need to be depleted first. Your doctor will monitor your thyroid function with regular blood tests and adjust the dose accordingly.
Thacapzol can cause birth defects and should be used during pregnancy only if the benefits clearly outweigh the risks. Women who can become pregnant should use reliable contraception during treatment. If you become pregnant while taking Thacapzol, contact your doctor immediately. In the first trimester, propylthiouracil (PTU) is generally preferred as it has a lower teratogenic risk. In some cases, treatment with thiamazole may continue with close monitoring if hyperthyroidism poses a greater risk to the mother and fetus.
The most serious side effects include agranulocytosis (a severe drop in white blood cells that impairs the immune system), hepatotoxicity (liver damage), and acute pancreatitis. Agranulocytosis typically presents with sudden fever, sore throat, or mouth ulcers and most commonly occurs within the first 3 months of treatment. If you experience any of these symptoms, seek immediate medical attention and have a blood test to check your white blood cell count.
Thiamazole (also known as methimazole) and carbimazole are closely related antithyroid drugs. Carbimazole is a prodrug that is rapidly converted to thiamazole in the body. Both work by the same mechanism — inhibiting thyroid peroxidase — but thiamazole is the active form. In some countries, carbimazole is more commonly prescribed (e.g., the UK), while in others thiamazole is preferred. The dosing differs slightly because approximately 10 mg of carbimazole yields about 6 mg of thiamazole.
Thacapzol should be stored in its original packaging to protect from light. Keep it at room temperature, away from moisture, and out of reach of children. Do not use after the expiry date printed on the label. Unused or expired medicine should be returned to a pharmacy for proper disposal and should not be thrown in household waste or flushed down the drain.
References and Medical Sources
All medical information in this article is based on internationally recognized guidelines and peer-reviewed sources. Evidence level: 1A (systematic reviews and randomized controlled trials).
- Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229
- Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. doi:10.1159/000490384
- European Medicines Agency (EMA). Thiamazole — Summary of Product Characteristics. EMA, 2024.
- British National Formulary (BNF). Carbimazole and Thiamazole. National Institute for Health and Care Excellence (NICE), 2024.
- World Health Organization. WHO Model List of Essential Medicines — 23rd List. WHO, 2023. Thiamazole is listed as an essential medicine for thyroid disorders.
- Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94(6):1881-1882. doi:10.1210/jc.2009-0850
- Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab. 2016;101(4):1606-1614. doi:10.1210/jc.2015-4274
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which consists of licensed physicians with specialist expertise in endocrinology, internal medicine, and clinical pharmacology. All medical content follows the GRADE evidence framework and is based on current international guidelines.
Medical Writing
iMedic Medical Editorial Team — Specialists in Endocrinology and Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel reviewing content according to ATA and ETA guidelines
All medical content on iMedic is evidence-based (Level 1A), reviewed by specialist physicians, and updated regularly to reflect current guidelines. We have no commercial funding and accept no pharmaceutical industry sponsorship. Read our full editorial standards.